ENTA Quote, Financials, Valuation and Earnings

Nanoviricides has a net margin of -131.44% compared to Enanta Pharmaceuticals's net margin of --. Enanta Pharmaceuticals's return on equity of -70.18% beat Nanoviricides's return on equity of --.

Enanta Pharmaceuticals has a consensus price target of $15.14, signalling upside risk potential of 184.64%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 360.99%. Given that Nanoviricides has higher upside potential than Enanta Pharmaceuticals, analysts believe Nanoviricides is more attractive than Enanta Pharmaceuticals.

Enanta Pharmaceuticals has a beta of 0.811, which suggesting that the stock is 18.902% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals quarterly revenues are $17M, which are larger than Nanoviricides quarterly revenues of --. Enanta Pharmaceuticals's net income of -$22.3M is lower than Nanoviricides's net income of -$2M. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.69x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -131.44% compared to Enanta Pharmaceuticals's net margin of --. Enanta Pharmaceuticals's return on equity of -70.18% beat Oragenics's return on equity of --.

Enanta Pharmaceuticals has a consensus price target of $15.14, signalling upside risk potential of 184.64%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 455.56%. Given that Oragenics has higher upside potential than Enanta Pharmaceuticals, analysts believe Oragenics is more attractive than Enanta Pharmaceuticals.

Enanta Pharmaceuticals has a beta of 0.811, which suggesting that the stock is 18.902% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals quarterly revenues are $17M, which are larger than Oragenics quarterly revenues of --. Enanta Pharmaceuticals's net income of -$22.3M is lower than Oragenics's net income of -$3.3M. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.69x versus 1.12x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Internet Patents Corporation has a net margin of -131.44% compared to Enanta Pharmaceuticals's net margin of --. Enanta Pharmaceuticals's return on equity of -70.18% beat Internet Patents Corporation's return on equity of --.

Enanta Pharmaceuticals has a consensus price target of $15.14, signalling upside risk potential of 184.64%. On the other hand Internet Patents Corporation has an analysts' consensus of -- which suggests that it could fall by --. Given that Enanta Pharmaceuticals has higher upside potential than Internet Patents Corporation, analysts believe Enanta Pharmaceuticals is more attractive than Internet Patents Corporation.

Enanta Pharmaceuticals has a beta of 0.811, which suggesting that the stock is 18.902% less volatile than S&P 500. In comparison Internet Patents Corporation has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Internet Patents Corporation offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. Internet Patents Corporation pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals quarterly revenues are $17M, which are larger than Internet Patents Corporation quarterly revenues of --. Enanta Pharmaceuticals's net income of -$22.3M is higher than Internet Patents Corporation's net income of --. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while Internet Patents Corporation's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.69x versus -- for Internet Patents Corporation. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -131.44% compared to Enanta Pharmaceuticals's net margin of --. Enanta Pharmaceuticals's return on equity of -70.18% beat Theriva Biologics's return on equity of --.

Enanta Pharmaceuticals has a consensus price target of $15.14, signalling upside risk potential of 184.64%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 832.84%. Given that Theriva Biologics has higher upside potential than Enanta Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Enanta Pharmaceuticals.

Enanta Pharmaceuticals has a beta of 0.811, which suggesting that the stock is 18.902% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals quarterly revenues are $17M, which are larger than Theriva Biologics quarterly revenues of --. Enanta Pharmaceuticals's net income of -$22.3M is lower than Theriva Biologics's net income of -$4.4M. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.69x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.